Diabetes Mellitus Clinical Trial
Official title:
Can HbA1c Replace OGTT for the Diagnosis of Diabetes Mellitus Among Chinese Patients With IFG?
| Verified date | March 2016 |
| Source | The University of Hong Kong |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Hong Kong: Ethics Committee |
| Study type | Observational |
This is a cross-sectional study that aims to assess the sensitivity and specificity of using
HbA1c as a diagnostic test for detecting the presence of diabetes mellitus (DM) when
compared to the use of oral glucose tolerance test (OGTT) among Hong Kong Chinese adult who
have impaired fasting glucose (IFG).
The investigators will recruit around 1000 non-diabetic adult participants who have impaired
fasting glucose (i.e. fasting glucose level between 5.6 to 6.9mmol/L) AND without symptoms
of hyperglycaemia to undergo both HbA1c test and oral glucose tolerance test after obtaining
their informed consent. A diagnosis of DM is confirmed when both the fasting glucose level
and 2-hour-post challenge plasma glucose level fall into diabetic range (i.e. fasting
glucose level ≥7.0mmol/L and 2-hour-post challenge plasma glucose level ≥11.1mmol/L) after a
standard 75g OGTT. Participants with only 1 plasma glucose value within the diabetic range
will be invited to repeat an oral glucose tolerance test for confirmation of their diagnosis
as recommended by American Diabetes Association and World Health Organization. Demographic
data of the participants including age, gender, smoking status, medical history, diet and
activity level will be collected. Lipid profile, blood pressure, waist circumference and
body mass index will be checked and the total cardiovascular risk in 10 years will be
calculated for each participant using the Joint British Societies 2005 and Framingham 2008
equations to evaluate the baseline cardiovascular risk of the participants.
These data will be analyzed using SPSS. The primary outcomes are the sensitivity and
specificity of HbA1c in detecting diabetes mellitus diagnosed by oral glucose tolerance test
(the gold standard). A receiver operating characteristic (ROC) curve will be obtained by
plotting sensitivity against (1-specificity) for each cutoff value for identification of an
optimal cutoff point. Diagnostic accuracy will be assessed by the area under the curve
(AUC). The differences in characteristics among participants diagnosed to have diabetes
mellitus by oral glucose tolerance test or HbA1c will be compared using independent t-test
or χ2 test for comparison between the 2 groups.
| Status | Completed |
| Enrollment | 1357 |
| Est. completion date | March 2015 |
| Est. primary completion date | March 2015 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Aged = 18 year - Chinese ethnicity - Diagnosis of impaired fasting glucose (i.e. FG between 5.6-6.9mmol/L) identified from latest blood test results within 18 months prior to recruitment) Exclusion Criteria: - Known history of diabetes mellitus or on hypoglycaemic treatment - Having symptoms of hyperglycaemia at recruitment - Women who are pregnant or breast-feeding at recruitment - Patients taking glucocorticoid at recruitment - Active and uncontrolled thyroid diseases (including subjects on thyroid replacement therapy or anti-thyroid drugs) or active endocrine diseases such as Cushing's syndrome or Acromegaly at recruitment - Clinically significant anaemia at recruitment - Severe renal impairment i.e. eGFR = 30 ml/min/1.73m2 - History of blood donation or blood transfusion within 3 months prior to recruitment |
Observational Model: Cohort, Time Perspective: Cross-Sectional
| Country | Name | City | State |
|---|---|---|---|
| Hong Kong | Ap Lei Chau General Out-patient Clinic | Hong Kong | |
| Hong Kong | Lek Yuen General Out-patient Clinic | Hong Kong | |
| Hong Kong | Tsan Yuk Hospital RAMP Clinic | Hong Kong |
| Lead Sponsor | Collaborator |
|---|---|
| The University of Hong Kong | Chinese University of Hong Kong |
Hong Kong,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | The sensitivity of the use of HbA1c | The sensitivity of the use of HbA1c at different cut points for diagnosing DM among Chinese adult patients with IFG compared to OGTT as the gold standard. | around 12-16 weeks after the study completed | No |
| Primary | The specificity of the use of HbA1c | The specificity of the use of HbA1c at different cut points for diagnosing DM among Chinese adult patients with IFG compared to OGTT as the gold standard. | around 12-16 weeks after the study completed | No |
| Secondary | The optimal cut-off level of HbA1c | The optimal cut-off level of HbA1c for diagnosing DM among Chinese adult patients with IFG | around 12-16 weeks after the study completed | No |
| Secondary | OGTT criteria in Chinese | The prevalence of DM among Chinese adult patients with IFG defined by OGTT criteria | around 12-16 weeks after the study completed | No |
| Secondary | HbA1c criteria in Chinese | The prevalence of DM among Chinese adult patients with IFG defined by HbA1c criteria | around 12-16 weeks after the study completed | No |
| Secondary | Cardiovascular risk | Difference in cardiovascular risk between patients who are diagnosed to have DM by HbA1c criteria compared to OGTT criteria | around 24-48 weeks after the study completed | No |
| Secondary | DM risk | Difference in DM risk between patients who are diagnosed to have DM by HbA1c criteria compared to OGTT criteria | around 24-48 weeks after the study completed | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
| Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
| Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
| Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
| Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
| Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
| Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
| Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
| Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
| Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
| Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
| Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
| Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
| Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
| Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
| Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |